Irbesartan Basi

Irbesartan, the active ingredient in Irbesartan Basi, is a Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It treats hypertension and related cardiovascular conditions in adults.

GNH USA supplies Irbesartan Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an angiotensin II receptor blocker that acts on the renin‑angiotensin system to manage several cardiovascular and renal conditions.

Hypertension: lowers blood pressure and reduces risk of cardiovascular events. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Heart failure: improves symptoms and decreases hospitalizations in chronic heart failure patients.

Irbesartan may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension (marked drop in blood pressure) - Acute kidney injury (sudden decline in renal function) - Elevated liver enzymes (signs of hepatic injury)

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure safe use.

- Monitor blood pressure: check regularly to assess therapeutic response. - Assess renal function: evaluate serum creatinine and eGFR before and during treatment. - Check serum potassium: watch for hyperkalaemia, especially with concomitant potassium‑sparing agents. - Use cautiously in hepatic impairment: dose adjustment may be required. - Avoid use in pregnancy: drug is contraindicated due to risk of fetal toxicity. - Store at ambient temperature: keep in original packaging, protect from moisture.

Irbesartan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Aliskiren in patients with diabetes: combined use may increase risk of renal dysfunction, hyperkalaemia, and hypotension. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium. - ACE inhibitors: concurrent use can lead to additive renal impairment and hyperkalaemia.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Irbesartan plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce Irbesartan effectiveness.